Forest Labs buys Furiex for bowel drug


Forest Laboratories has agreed to buy Furiex pharmaceuticals for $1.1 billion (£650 million) in cash, with a top-up of up to $360 million contingent on approval of Furiex’s irritable bowel syndrome drug eluxadoline.

The drug will mesh quite well with Forest’s other gastrointestinal drug lines, many of which came from its acquisition of Aptalis at the beginning of the year. True to the company’s focus on innovative drugs, Forest has also said that, as soon as the deal goes through, it will sell Furiex’s royalty rights to diabetes drug alogliptin and premature ejaculation remedy Priligy (dapoxetine) to investment firm Royalty Pharma.

There is an interesting twist to the approval contingency payment, too. Because eluxadoline is an opioid receptor agonist, there is a possibility that it will be classified as a controlled substance by the US Drug Enforcement Agency (DEA). If this happens, the value of the top-up payment will go down depending on the level of restriction the DEA imposes.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

29 March 2011 Business

news image

Industry news, April 2011

Most Read

Cannabis chemists look for professional recognition

16 October 2014 News and Analysis

news image

The American Chemical Society is being petitioned to form a division to help develop standards in the field

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

Most Commented

UCLA spent $4.5 million on legal costs in Sangji case

20 October 2014 News and Analysis

news image

University defends spending in case brought against chemistry professor, highlighting $20 million investment in lab safety

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines